Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1

NANot yet recruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
SclerodermaSystemic Sclerosis
Interventions
OTHER

Plain-language summary

Participants will receive information about a research study via a plain-language summary. The comparator will be a plain-language summary, since plain-language summaries are commonly used and more easily developed than other tools. The summary will be designed based on Canadian government and other key recommendations, including from the Cochrane Collaboration. It will include Background and Objectives, Methods, Results, Limitations, and Key Message for Patients sections and include information on how evidence informs knowledge or health care options. Abstract will be \< 500 words long and use short, positive, active-voice sentence structures and everyday words. Reading level will be between 8th and 9th grade based on Flesch-Kincaid Grade Level and readability score between 60 and 70 based on Flesch Reading Ease.

OTHER

Dissemination Tool (Infographic)

The infographic will be developed based on key principles including clearly defining the audience and purpose; sharing a story, rather than just facts, with brief, clear messaging; highlighting main ideas; using an attractive title and images; and following principles of good graphic design.

All Listed Sponsors
lead

Lady Davis Institute

OTHER

NCT06373263 - Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1 | Biotech Hunter | Biotech Hunter